Gergely V.
- Country
- Hungary
- Department
- Department of Internal Medicine and Haematology
Research Overview
- A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
- Tailored Ibrutinib and Venetoclax Regimens in Untreated Chronic Lymphocytic Leukemia: A Multicohort Efficacy Evaluation
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
Data & Insights
Has run more than one trial at 141 of 270 partner sites.
Specializations
Hematologic Malignancies
Specializes in investigating novel treatments for chronic lymphocytic leukemia and multiple myeloma, with particular focus on targeted therapies and combination treatment approaches.
- B-cell lymphomas
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Acute myeloid leukemia
Actively explores innovative therapeutic combinations including targeted agents and immunotherapies.
Blood Disorders
Focuses on research in various hematologic conditions, particularly autoimmune hematologic disorders and bone marrow disorders.
- Neutropenia
- Polycythemia vera
- Essential thrombocythemia
- Paroxysmal nocturnal hemoglobinuria
Investigates treatments for primary and secondary immunodeficiencies affecting blood components.
Cardiovascular and Thrombotic Conditions
Conducts research in cardiovascular diseases and thrombotic disorders, with emphasis on novel therapeutic approaches.
- Chronic heart failure
- Deep vein thrombosis
- Immune thrombocytopenia
Studies innovative treatments for both acute and chronic cardiovascular conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.